

Hawai'i Health Partners Webinar: Adult Congenital Heart Disease

Tuesday, October 21, 2025
12:30pm—1:30pm via Zoom

**HAWAI'I
PACIFIC
HEALTH**

HAWAI'I
HEALTH
PARTNERS

CONFERENCE INFORMATION

GENERAL OBJECTIVES:

This offering is intended for Physicians, Nurses and other health care professionals.

By the end of the course, the participants will be able to:

1. Comprehend the changing demographics of adults with congenital heart conditions.
2. Delineate the unique medical challenges faced by adults with congenital heart disease.
3. Integrate ACHD care in primary and cardiology specialty care management.
4. Improve the quality of care for ACHD patients based on a multi-modality approach.

CONTINUING EDUCATION:



In support of improving patient care, Hawai'i Pacific Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Hawai'i Pacific Health designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credits™* for physicians. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Hawai'i Pacific Health designates this live activity for 1.0 contact hours for nurses. Nurses should only claim credit commensurate with the extent of their participation in the activity.

TO CLAIM CE:

Please note that in order to receive continuing education credits for this offering, you must:

- Be registered for this activity and Sign in.
- Claim credit commensurate with the extent of your participation in the activity.
Speakers cannot claim credit for their own presentations.
- Complete and submit the evaluation survey that will be emailed to you within one week of the offering.
- Your CE certificate will be immediately available to you upon completion of your evaluation.

DISCLOSURE INFORMATION:

Per CE requirements, a disclosure report is included below listing any relationships that faculty, planners and others in control of educational content may have with an ineligible company. An Ineligible Company, as defined by the ACCME, is a company whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.


The following Faculty, Planners, and Others in control of educational content have reported no relationships with any ineligible company as defined by the ACCME new "Standards for Integrity and Independence in Accredited Continuing Education":

Webinar Information

- You have been automatically muted
 - You cannot unmute yourself
- You will be able to submit questions via the Q&A section
- This webinar counts for HQIP credit for the measure HHP Network Engagement - Webinars

Adult Congenital Heart Disease

Opportunity for a state-wide collaboration



Andras Bratincsak, MD, PhD

Professor of Pediatrics, University of Hawaii, John A. Burns School of Medicine
Pediatric and Adult Congenital Cardiology, Hawaii Pacific Health Medical Group

October 21, 2025

**HAWAI'I
PACIFIC
HEALTH**

**HAWAI'I
HEALTH
PARTNERS**

Disclosure

I do not have any financial conflict of interest to disclose.


Objectives

- Describe the overall **disease complexity and survival** of adults with congenital heart conditions
- Discuss the importance of **continued health care** for adults with congenital heart defects
- Outline strategic **collaborative care model** for sophisticated ACHD care involving the primary care providers and cardiologists

CONGENITAL

HEART DISEASE

1 in 100 live births



Congenital Heart Disease in numbers

About 1% of live births have CHD

33000 children born with CHD annually in USA

190 children born with CHD annually in Hawai'i

Natural history of CHD


Percentage of Total Mortality Occurring by One Month and One Year

	32		25	
	< 1 mo	< 1 yr	< 1 mo	< 1 yr
VSD	30	72	65	87
PDA	22*	58*	100†	
ASD secundum, primum or A-V canal	18‡§	53‡§	100	83
Pulmonic stenosis	40	70		
Aortic stenosis			30	70
Coarctation of aorta (preductal)		~66	87	100
Tetralogy of Fallot	14	63*	50	75**
Transposition of great arteries	51	83	40	95
Truncus arteriosus	>29††	78‡¶	100	
Tricuspid atresia	15‡	66	0	100
Pulmonic atresia: VSD			25	75
No VSD	63‡	88	50	75
Aortic and mitral atresia	94‡	100	83	100
Total anomalous pulmonary venous drainage	34	90	67	100

Average mortality
of CHD by 1 year
of age:

80%


Complexity of the most common CHD




Improvement of survival




Early computer



Survival of patients by 2000




Distribution of children and adults with CHD



1965

Children and adults with CHD



Congenital Heart Disease in Hawai'i

190 children born with CHD annually

90% of children survive to adulthood


170 children with CHD graduate annually

over 10000 ACHD patients by 2030

Tidal wave of ACHD patients



Survival of adults with CHD



A population-based prospective evaluation of risk of Sudden cardiac death after operation for common CHDs. Silka MJ, et al. JACC. 1998;32:245-251.



The problem is ...

There are many ACHD patients (1% of the population)

Their disease is complicated

They are sick to start with

Morbidity and mortality is significant

Suboptimal care costs a lot of money

Case #1 – 44 y/o woman with dilated right ventricle

She was referred to cardiology, because of feeling tired with exercise at 27 years of age

Echocardiogram found dilated right ventricle


No ASD by TTE and TEE

No shunting seen


No evidence of pulmonary hypertension by cath

Fast forward 17 years – referred to ACHD clinic

Case #1 – 44 y/o woman with dilated right ventricle



Case #1 – 44 y/o woman with dilated right ventricle



12 x 192

S

1003303 (44

RV_2CH_cine — RV

Case #1 – 44 y/o woman with dilated right ventricle

Underwent Warden procedure at 44 years of age: surgical channeling of partial anomalous pulmonary venous return and closing of atrial septal defect

Recovered in 3 months

Exercise intolerance improved dramatically

ACHD patients

Over 100 different congenital conditions

Tailored cardiology care with specific instructions about medical management and interventions

ACHD guidelines

ACHD is a guideline-directed subspecialty

Circulation

AHA/ACC GUIDELINE

2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Patients with ACHD who are cared for in ACHD centers have better outcomes than those cared for in centers without ACHD expertise, **S1.4-9** and this need for specialized care is noted

Recognition of Adult Congenital Heart Disease

American Board of Medical Specialties

ACC subgroup



ABIM Board certification



2 years of subspecialty training after cardiology



Subspecialties

Adult Congenital Heart Disease

An internist or pediatrician who specializes in Adult Congenital Heart Disease has the unique knowledge, skills and practice required of a cardiologist for evaluating and delivering high quality lifelong care for a wide range of adult patients with heart disease diagnosed at birth.

Advanced Heart Failure and Transplant Cardiology

An internist who specializes in Heart Failure and Transplant Cardiology has the special knowledge and skills required of cardiologists for evaluating and optimally managing patients with heart failure, particularly those with advanced heart failure, those with devices, including ventricular assist devices, and those who have undergone or are awaiting transplantation.

Cardiovascular Disease

An internist who specializes in diseases of the heart and blood vessels and manages complex cardiac conditions, such as heart attacks and life-threatening abnormal

[ABIM Blog](#)

[BECOMING CERTIFIED](#)

[MAIN](#)

[Home](#) > [Becoming Certified](#) > [Policies](#) > [Internal Medicine and Subspecialty Policies](#) >

ADULT CONGENITAL HEART DISEASE POLICIES

ACHD centers

ACHA accreditation


ACHA ACHD Accreditation

Help the Adult Congenital Heart Association improve the quality of care for adult heart disease.




ACHA ACHD PROGRAM CRITERIA Comprehensive Care Center	
A.	ACHD Cardiologist
B.	ACHD Medical Program Director
C.	Advanced Practice Nurse/Physician Assistant
D.	Registered Nurse
E.	Cardiothoracic Surgery and Cardiothoracic Intensive Care Unit
F.	Heart Failure, Heart Transplant, Heart/Lung Transplantation
G.	Interventional Cardiac Catheterization
H.	Interventional Electrophysiology
I.	Inpatient Services
J.	Outpatient Services
K.	Transitional Services
L.	Patient-Centered Care
M.	Echocardiography
N.	Cardiac Magnetic Resonance Imaging
O.	Cardiac Computed Tomography
P.	Pulmonary Arterial Hypertension
Q.	Exercise Testing and Cardiac Rehabilitation
R.	Reproductive Services
S.	Psychology and Social Work
T.	Cardiac Anesthesia

ACHD centers across United States




ACHD center in Hawaii



 ACHD Board Certified Physician

City	State	Institution	Medical Director
Honolulu	HI	ACHD Clinic of Hawaii Pacific Health Straub Medical Center (808) 522-4222	Andras Bratincsak, MD 
Honolulu	HI	ACHD Clinic of Hawaii Pacific Health Satellite Clinic #1 - Honolulu, HI (808) 522-4222	Andras Bratincsak, MD 

ACHD center in Hawaii



ACHD newsletter

Hawaii Pacific Health

Adult Congenital Heart Disease Clinic

ADULT CONGENITAL HEART DISEASE

HAWAII PACIFIC HEALTH MEDICAL GROUP



WHO WE ARE

JOHN VERULA, APRN



WHO WE ARE

ANDRAS BRATINCSAK, MD, PHD



WHO WE ARE

KIM KOYANAGI, APRN



PEDIATRIC HEART CENTER AT KMCWC -
ADULT CONGENITAL HEART DISEASE

1319 Punahou St., Suite 950

Honolulu, HI 96826

T: (808) 983-8933

F: (808) 957-9770

HEART CENTERS

HAWAII
PACIFIC
HEALTH

KAPI'OLANI
PALI MOMI
STRAUB BENIOFF
WILCOX

Creating a healthier Hawaii

STRAUB BENIOFF HEART CENTER -
ADULT CONGENITAL HEART DISEASE

888 S King Street

Honolulu, HI 96813

T: (808) 522-4222

F: (808) 522-4065


June 2025

1

Adult Congenital Heart Disease Clinic

PATENT DUCTUS ARTERIOSUS

Patent Ductus Arteriosus




The persistence of a Patent Ductus Arteriosus (PDA) can present varying degrees of clinical significance, largely depending on its size. Due to the higher pressure in the aorta compared to the pulmonary arteries, a PDA can result in increased pulmonary blood flow. This can manifest as a characteristic systolic-diastolic machinery murmur at the left upper sternal border.

- **Small PDA:** Typically asymptomatic, producing only a murmur without clinical consequences.
- **Moderate to large PDA:** Excess pulmonary circulation may progress to volume overload, increasing the risk of left-sided heart failure and contributing to symptoms such as dyspnea and fatigue.
- **Unrecognized large PDA:** If undiagnosed in childhood, prolonged pulmonary overcirculation can lead to pulmonary arterial hypertension (PAH), which may become irreversible and life-threatening.


- **Silent PDA:** In cases where the PDA is exceptionally small, auscultation may not reveal a murmur. These are often incidental findings on echocardiography and generally do not require intervention.

Early identification and appropriate management of PDA in adulthood are critical for preventing complications such as heart failure, pulmonary hypertension, and Eisenmenger syndrome (where there is right-to-left shunt). Without intervention, larger PDAs place individuals at high risk for life-threatening complications. Early diagnosis and closure – either through catheter-based device closure or surgical ligation – can prevent many of these long-term consequences.

Closure by Device



Closure by Tying Off



Transcatheter intervention is available locally at our Heart Center.

We are ready to serve you!

June 2025

3

HAWAII
PACIFIC
HEALTH

HAWAII
HEALTH
PARTNERS

Multidisciplinary team approach

ACHD cardiologist

Congenital heart surgeon

ACHD interventional cardiologist

Heart failure specialist


Electrophysiologist

Additional adult specialists (GI, pulm, neuro)

Psychologist, psychiatrist


Social services

Distribution of adults with CHD



- VSD
- ASD
- PDA
- AVSD
- PS
- AS
- CoA
- TOF
- TGA
- BAV
- other

Distribution of visits with adult CHD patients



Complexity & acuity –based visit schedule

Complexity 1: simple lesions without any complication (VSD, repaired VSD, small ASD, repaired ASD, repaired PAPVR) – annual telephone calls, q4years echo and monitor, q4years visit with APP

Complexity 2: simple lesions with mild complications (repaired VSD with mild AI, repaired ASD with residual shunting, repaired PAPVR with arrhythmia) – annual telephone calls, q2years echo and monitor, q2years visit with APP or q4years visit with ACHD specialist

Complexity 3: moderate lesions (D-TGA s/p ASO, TOF s/p repair, AVSD s/p repair with mild to moderate regurgitation) – annual telephone calls, q1year echo and monitor, q1-2years visit with APP and q2 years visit with ACHD specialist depending on disease severity

Complexity 4: moderate lesions with complications or complex lesions with no problems (D-TGA s/p Mustard, arrhythmias, Fontan in good shape) – q6months telephone calls, q6-12 months echo and monitor, q1years visit with APP and/or ACHD specialist depending on disease severity

Complexity 5: complex lesions with problems (failing Fontan, D-TGA in heart failure, systemic right ventricle in CHF) – q3months telephone calls, q3-6 months echo and monitor, q3-6 months visit with APP and/or ACHD specialist depending on disease severity

Complexity & acuity –based visit schedule

Complexity 1: simple lesions without any complication (VSD, repaired VSD, small ASD, repaired ASD, repaired PAPVR) – annual telephone calls, q4years echo and monitor, q4years visit with APP

Complexity 2: simple lesions with mild complications (repaired VSD with mild AI, repaired ASD with residual shunting, repaired PAPVR with arrhythmia) – annual telephone calls, q2years echo and monitor, q2years visit with APP or q4years visit with ACHD specialist

Complexity 3: moderate lesions (D-TGA s/p ASO, TOF s/p repair, AVSD s/p repair with mild to moderate regurgitation) – annual telephone calls, q1year echo and monitor, q1-2years visit with APP and q2 years visit with ACHD specialist depending on disease severity

Complexity 4: moderate lesions with complications or complex lesions with no problems (D-TGA s/p Mustard, arrhythmias, Fontan in good shape) – q6months telephone calls, q6-12 months echo and monitor, q1years visit with APP and/or ACHD specialist depending on disease severity

Complexity 5: complex lesions with problems (failing Fontan, D-TGA in heart failure, systemic right ventricle in CHF) – q3months telephone calls, q3-6 months echo and monitor, q3-6 months visit with APP and/or ACHD specialist depending on disease severity

Complexity & acuity –based visit schedule

Complexity 1: simple lesions without any complication (VSD, repaired VSD, small ASD, repaired ASD, repaired PAPVR) – annual telephone calls, q4years echo and monitor, q4years visit with APP


Complexity 2: simple lesions with mild complications (repaired VSD with mild AI, repaired ASD with residual shunting, repaired PAPVR with arrhythmia) – annual telephone calls, q2years echo and monitor, q2years visit with APP or q4years visit with ACHD specialist

Complexity 3: moderate lesions (D-TGA s/p ASO, TOF s/p repair, AVSD s/p repair with mild to moderate regurgitation) – annual telephone calls, q1year echo and monitor, q1-2years visit with APP and q2 years visit with ACHD specialist depending on disease severity

Complexity 4: moderate lesions with complications or complex lesions with no problems (D-TGA s/p Mustard, arrhythmias, Fontan in good shape) – q6months telephone calls, q6-12 months echo and monitor, q1years visit with APP and/or ACHD specialist depending on disease severity

Complexity 5: complex lesions with problems (failing Fontan, D-TGA in heart failure, systemic right ventricle in CHF) – q3months telephone calls, q3-6 months echo and monitor, q3-6 months visit with APP and/or ACHD specialist depending on disease severity

Collaborative Care Model



What can we do at HPH?

Only ACHD center in Hawai'i at Kapi'olani Medical Center

Involve ACHD specialist for **every adult with CHD**

Share resources across facilities

Consultation services for all patients = collaborative care


Summary

Survival to adulthood of children with CHD is excellent
Tsunami of ACHD patients is coming (1% of population)
Half of them have complex CHD requiring specialty care
Morbidity and mortality rates are higher than average
ACHD care improves survival and decreases cost

Collaborative care model is the only way to provide care
for every ACHD patient in the state of Hawai'i

“An ounce of prevention is worth a pound of cure.”

Benjamin Franklin



**HAWAI‘I
PACIFIC
HEALTH**

HAWAI‘I
HEALTH
PARTNERS

Mahalo for listening!


**HAWAI'I
PACIFIC
HEALTH**

HAWAI'I
HEALTH
PARTNERS

Next HHP Webinar: (for HQIP credit)

Thursday, November 6, 2025 | 5:30-6:30 pm
OpenEvidence
By Dr. Mark Baker

To view upcoming HHP webinars and future events, please visit our [Hawai'i Health Partners website](#) for the “**Events Calendar**” from the “For Providers” dropdown.



For Specialists Only: (for HQIP credit)

- **Annual Assessment of Chronic Conditions Presentation #2 coming October 31, 2025**
- **Deadline for completion: December 31, 2025**
- **This measure is separate from HHP Network Engagement – Webinars**

For Eligible HHP Members:

ABMS Part 4 Continuing Certification Credit

- HHP members who met 50% of their potential HQIP earnings by September 30 were sent an attestation form
- Deadlines to complete:
 - October 31 for American Board of Obstetrics and Gynecology
 - November 26 for All Other Boards

Real Time Prescription Benefits

What is Real Time Prescription Benefits?

Real-Time Prescription Benefits (RTPB) provides the Prescriber with actionable price information that can be used in the prescribing decision and conversation with the patient.



The price shown is the price that the patient can expect to pay. It is based on their individual drug plan and drug spend for the year. It calculates the cost that would be owed by the patient, with the cost of a selected drug and their most common alternatives, along with the price of those drugs listed by the pharmacy.



Benefits include:

Can see out of pocket cost

Can see cost of alternative medications including mail order

Quickly replace current medication with a cheaper alternative

See prior authorization requirements

Order Entry

1. Enter medication order
2. Select a pharmacy
3. Sign the order. Real Time Prescription Benefits functionality will automatically display if there is actionable information with lower cost alternatives, coverage status changes.

Patient Estimates

**Preliminary Patient Estimate**
for Edgar B Marthom seen on 11/15/2023

Prescriptions

 using PRO-MI_54474 (PROINFORMA ...)

☒ Doxycycline Hyclate 50 MG TBEC
Shollenberger Pharmacy (P..., 28 tab, ≈14 days
Prior Authorization required

\$35
\$2.52/day

Payer-Suggested Alternatives

☐ doxycycline (PERIOSTAT) 20 MG tablet Rapid-Rx Online Pharm..., 28 tab, 14 days	\$9 \$0.62/day
☐ doxycycline (VIBRAMYCIN) 50 MG CAPS capsule Rapid-Rx Online Pharm..., 28 cap, 14 days	\$9 \$0.63/day
☐ minocycline (MINOCIN) 50 MG CAPS capsule Rapid-Rx Online Pharm..., 28 cap, 14 days	\$9 \$0.63/day
☐ doxycycline (PERIOSTAT) 20 MG tablet Shollenberger Pharmac..., 28 tab, 14 days	\$10 \$0.69/day
☐ doxycycline (VIBRAMYCIN) 50 MG CAPS capsule Shollenberger Pharmac..., 28 cap, 14 days	\$10 \$0.71/day

Patient portion (per fill): **\$35**

 Accept

 Close

Cologuard Home Kit Campaign

HMSA in partnership with Exact Sciences

1. Campaign Overview:

- HMSA is conducting an EOY push to close colorectal cancer screening gaps for Medicare Stars. Eligible members are being sent Cologuard kits at no cost.
- Exact Sciences mailed member notification letters followed by at-home Cologuard kits to MA members with an open colorectal cancer screening gap.
- Notifications were sent to PCPs via fax between 9/24/25 and 10/2/2025.
- Test results will be faxed directly to the attributed provider, and any positive results will require a follow-up colonoscopy.
- Patients are also contacted directly by Exact Sciences regarding their results
 - HHP has requested HMSA to send over patient-level reporting with results

2. Questions/Feedback:

1. Please email info@hawaiihealthpartners.org

Medication Adherence Outreach

HMSA with Curant Health

Key Takeaways:

- Outreach to MA patients started on Monday, 10/6/25
- Curant Health will not change or discontinue a patient's medication(s). Curant Health will contact the patient's provider for any medication concerns
- An opt-out option for providers is not available at this time
- For any questions or concerns please email, info@hawaiihealthpartners.org

Program Focus: Medicare Stars Program - Medication Adherence Measures

Program Overview

HMSA is partnering with Curant Health to support Medicare members to improve medication adherence and overall health outcomes at no additional cost to the member. Curant Health's clinical team consists of nurses, pharmacists, medical assistants, and pharmacy technicians who help identify barriers to adherence, provide education, help resolve therapy gaps, and coordinate care with providers. Outreach is tailored based on clinical need, ranging from digital engagement to personalized care management.

Key Program Support

- **Digital messaging:** Education, adherence support, and preventive care.
- **Personalized outreach:** Based on clinical risk to influence member behavior.
- **Ongoing support:** Barrier resolution, education, and encouragement.
- **Dedicated care manager:** For members needing additional support.
- **Motivational interviewing:** Addresses challenges to adherence.
- **Pharmacist support:** Reviews medication and provider coordination.

What Providers Should Expect

- **Member outreach:** Curant Health may contact members by phone, text, email, or mail to provide education, refill reminders, and health support.
- **Care coordination:** Curant Health may reach out to providers to resolve therapy gaps or coordinate care.

Provider Action

If members have questions about the program, please refer them to Curant Health at:

 **1 (866) 202-7294** (9 a.m.-6 p.m.)

 **TTY: 711**

Curant Health Georgia, LLC, an independent company providing a medication adherence program for HMSA Medicare Advantage members on behalf of HMSA.

Thank you for joining us!

- A recording of the meeting will be available afterwards
- Unanswered question?
 - Contact us at Info@Hawaiihealthpartners.org